Perinatal Transmission of MDR Bacteria

Multi-antibiotic Resistance Clinical Trial

— ACQUIRE  

Official title:

Perinatal Transmission of Multi-drug Resistant (MDR) Bacteria

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06148480
• Other study ID #: IRB 2020-3331
• Status: Recruiting
• Start date: July 17, 2020
• Est. completion date: December 31, 2026

Study information

• Verified date: November 2023
• Source: Ann & Robert H Lurie Children's Hospital of Chicago
• Contact: Mehreen Arshad
• Phone: 3122274668
• Email: marshad[@]luriechildrens.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

We aim to conduct a prospective surveillance study of mothers and their infants born vaginally or by scheduled C-section and who are admitted to Northwestern Medicine Prentice Women's Hospital to determine the prevalence of ESBL-E carriage in healthy post-partum women and the transmission rate of these strains to their infants. Using whole genome sequencing and a comparative genomics approach we will determine the relatedness of strains among mother-infant dyads as well as identify genetic regions common to transmitted strains. We hypothesize that; 1) given the diverse population of Chicago there will be a significant rate of gut colonization with ESBL-E among mothers admitted to Prentice, 2) ESBL-E strains isolated from neonates will be identical to those from their mothers and 3) genetic determinants of transmission are conserved across ESBL E. coli strains that are perinatally transmitted. These hypotheses will be tested using the following Aims:

Aim 1: Determine the prevalence of ESBL-E gut colonization and rate of perinatal transmission among mother-infant dyads Aim 2: Identify genetic determinants of transmission common to ESBL E. coli that are perinatally transmitted.

Our long-term goal is to understand the unique features of persistent gut and vaginal ESBL-E colonizers and identify genetic and molecular elements that could be attractive therapeutic targets to decrease the burden of ESBL-E colonization and perinatal transmission.

Description:

The rapid rise of multi-drug resistant Enterobacteriaceae (MDR-E) is severely threatening the way we treat common infectious diseases. A particularly vulnerable population are neonates where a delay in the treatment of MDR-E sepsis can be fatal. Additionally, highly drug resistant bacteria such as the pandemic E. coli ST131 strain are persistent gut and vaginal colonizers (1). In animal models of gut colonization, these strains out-compete drug-sensitive, commensal Escherichia coli. Early life exposure to MDR-E could, therefore, have long-lasting effects on the developing microbiome and overall child health (2).

Among extra-intestinal pathogenic Enterobacteriaceae, resistance against a number of antibiotics, especially the beta-lactams, has rapidly risen in the last decade. Since the gut is a major reservoir of these pathogens even in otherwise healthy individuals it is likely that there is a concomitant increase in gut colonization with extended spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) among the general population (3, 4). Even in regions with a low prevalence of community acquired ESBL-E infections, perinatal transmission occurs in 35% of infants born to mothers colonized with these strains (5). We and others have recently shown that healthy infants in South Asia, a region with a high use of antibiotics per capita, are carriers of ESBL-E (6). In vitro studies in our lab suggest that ESBL E. coli isolated from these infants have a higher growth potential than commensal E. coli. Using a murine model of perinatal transmission of E. coli, we have shown that some of the ESBL E. coli strains adept in human infant gut colonization can also readily colonize pregnant dams and be perinatally transmitted. The burden of ESBL-E colonization among pregnant women and their neonates in the US and the genetic determinants of perinatal transmission are unknown.

We aim to conduct a prospective surveillance study of mothers and their infants born vaginally and who are admitted to Northwestern Medicine Prentice Women's Hospital to determine the prevalence of ESBL-E carriage in healthy post-partum women and the transmission rate of these strains to their infants. Using whole genome sequencing and a comparative genomics approach we will determine the relatedness of strains among mother-infant dyads as well as identify genetic regions common to transmitted strains. We hypothesize that; 1) given the diverse population of Chicago there will be a significant rate of gut colonization with ESBL-E among mothers admitted to Prentice, 2) ESBL-E strains isolated from neonates will be identical to those from their mothers and 3) genetic determinants of transmission are conserved across ESBL E. coli strains that are perinatally transmitted. These hypotheses will be tested using the following Aims:

Aim 1: Determine the prevalence of ESBL-E gut colonization and rate of perinatal transmission among mother-infant dyads Aim 2: Identify genetic determinants of transmission common to ESBL E. coli that are perinatally transmitted.

Our long-term goal is to understand the unique features of persistent gut and vaginal ESBL-E colonizers and identify genetic and molecular elements that could be attractive therapeutic targets to decrease the burden of ESBL-E colonization and perinatal transmission.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Women that are admitted to Northwestern Medicine Women's Hospital that have delivered an infant vaginally or have had a scheduled C-section without preceding labor. Infants that are born vaginally who are healthy and do not require transfer to the NICU for any reason.

Exclusion Criteria:

Temperature >38 Celsius in labor, caesarean section after labor, rupture of membranes or done emergently, antibiotic use in last trimester including for GBS+, delivery at <35 weeks, immunocompromised host including being HIV+, infant requiring transfer to NICU for any reason and infants who are transferred to the NICU.

Related Conditions & MeSH terms

• E. Coli Infection
• Escherichia coli Infections
• Multi-antibiotic Resistance

Locations

Country	Name	City	State
United States	Prentice Women's Hospital	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Ann & Robert H Lurie Children's Hospital of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ESBL-E Prevalence	Determine the proportion of women in the post-partum period that are colonized with ESBL-E	Baseline
Primary	Transmission Among Mother-Infant Dyads	Determine the proportion of neonates that acquire ESBL-E strains perinatally	Baseline
Primary	Persistence of ESBL-E Colonization	For determine colonization of ESBL-E organisms in neonates 7 days after birth.	7 days from baseline
Secondary	Genetic Determinants of ESBL-E	Identifying specific genes that are important for successful perinatal transmission of ESBL-E	Baseline